Gunnar Norstdedt

Dr. Gunnar Norstdedt

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2007 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEnikö Sonkoly
Enikö Sonkoly
TWTianling Wei
Tianling Wei
PJPeter C.J. Janson
Peter C.J. Janson
ASAnnika Sääf
Annika Sääf
LLLena Lundeberg
Lena Lundeberg
APAndor Pivarcsi
Andor Pivarcsi
MicroRNAs are a recently discovered class of posttranscriptional regulators of gene expression with critical functions in health and disease. Psoriasis is the most prevalent chronic inflammatory skin disease in adults, with a substantial negative impact on the patients' quality of life. Here we show for the first time that psoriasis-affected skin has a specific microRNA expression profile when compared with healthy human skin or with another chronic inflammatory skin disease, atopic eczema. Among the psoriasis-specific microRNAs, we identified leukocyte-derived microRNAs and one keratinocyte-derived microRNA, miR-203. In a panel of 21 different human organs and tissues, miR-203 showed a highly skin-specific expression profile. Among the cellular constituents of the skin, it was exclusively expressed by keratinocytes. The up-regulation of miR-203 in psoriatic plaques was concurrent with the down-regulation of an evolutionary conserved target of miR-203, suppressor of cytokine signaling 3 (SOCS-3), which is involved in inflammatory responses and keratinocyte functions. Our results suggest that microRNA deregulation is involved in the pathogenesis of psoriasis and contributes to the dysfunction of the cross talk between resident and infiltrating cells. Taken together, a new layer of regulatory mechanisms is involved in the pathogenesis of chronic inflammatory skin diseases.

14 May 2007 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
MAMikael Altun
Mikael Altun
EEErik Edström
Erik Edström
ESEric Spooner
Eric Spooner
AFAmilcar Flores‐Moralez
Amilcar Flores‐Moralez
EBEsbjörn Bergman
Esbjörn Bergman
BUBrun Ulfhake
Brun Ulfhake

29 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MVMattias Vesterlund
Mattias Vesterlund
FZFahad Zadjali
Fahad Zadjali
TPTorbjörn Persson
Torbjörn Persson
MNMichael L. Nielsen
Michael L. Nielsen
BKBenedikt Kessler
Benedikt Kessler
AFAmilcar Flores-Morales
Amilcar Flores-Morales
Growth Hormone is essential for the regulation of growth and the homeostatic control of intermediary metabolism. GH actions are mediated by the Growth Hormone Receptor; a member of the cytokine receptor super family that signals chiefly through the JAK2/STAT5 pathway. Target tissue responsiveness to GH is under regulatory control to avoid excessive and off-target effects upon GHR activation. The suppressor of cytokine signalling 2 (SOCS) is a key regulator of GHR sensitivity. This is clearly shown in mice where the SOCS2 gene has been inactivated, which show 30–40% increase in body length, a phenotype that is dependent on endogenous GH secretion. SOCS2 is a GH-stimulated, STAT5b-regulated gene that acts in a negative feedback loop to downregulate GHR signalling. Since the biochemical basis for these actions is poorly understood, we studied the molecular function of SOCS2. We demonstrated that SOCS2 is part of a multimeric complex with intrinsic ubiquitin ligase activity. Mutational analysis shows that the interaction with Elongin B/C controls SOCS2 protein turnover and affects its molecular activity. Increased GHR levels were observed in livers from SOCS2−/− mice and in the absence of SOCS2 in in vitro experiments. We showed that SOCS2 regulates cellular GHR levels through direct ubiquitination and in a proteasomally dependent manner. We also confirmed the importance of the SOCS-box for the proper function of SOCS2. Finally, we identified two phosphotyrosine residues in the GHR to be responsible for the interaction with SOCS2, but only Y487 to account for the effects of SOCS2. The demonstration that SOCS2 is an ubiquitin ligase for the GHR unveils the molecular basis for its physiological actions.

4 May 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
FZFahad Zadjali
Fahad Zadjali
RSRuyman Santana‐Farre
Ruyman Santana‐Farre
MVMattias Vesterlund
Mattias Vesterlund
BCBerit Carow
Berit Carow
MMMercedes Mirecki‐Garrido
Mercedes Mirecki‐Garrido
AFAmilcar Flores‐Morales
Amilcar Flores‐Morales
Hepatic steatosis is a prominent feature in patients with growth hormone (GH) deficiency. The ubiquitin ligase SOCS2 attenuates hepatic GH signaling by inhibiting the Janus kinase 2 (JAK2)‐signal transducer and activator of transcription 5b (STAT5b) axis. Here, we investigated the role of SOCS2 in the development of diet‐induced hepatic steatosis and insulin resistance. SOCS2‐knockout (SOCS2 −/− ) mice and wild‐type littermates were fed for 4 mo with control or high‐fat diet, followed by assessment of insulin sensitivity, hepatic lipid content, and expression of inflammatory cytokines. SOCS2 −/− mice exhibited increased hepatic TG secretion by 77.6% ( P < 0.001) as compared with wild‐type control mice and were protected from high‐fat‐diet (HFD)‐induced hepatic steatosis, showing 49.3% ( P <0.01) reduction in liver TG levels compared to HFD‐fed wild‐type littermates. In contrast, we found that HFD‐triggered attenuation of systemic insulin sensitivity was more marked in SOCS2 −/− mice. Livers from the HFD‐fed SOCS2 −/− mice showed increased NF‐κB activity as well as elevated expression of genes for the inflammatory cytokines IFN‐γ and IL‐6. An inhibitory role of SOCS2 on Toll‐like receptor 4 signaling was demonstrated in macrophages obtained from the SOCS2 −/− and wild‐type mice. This study identified SOCS2 as an important regulator of hepatic homeostasis under conditions of high‐fat dietary stress.—Zadjali, F., Santana‐Farre, R., Vesterlund, M., Carow, B., Mirecki‐Garrido, M., Hernandez‐Hernandez, I., Flodström‐Tullberg, M., Parini, P., Rottenberg, M., Norstedt, G., Fernandez‐Perez, L., Flores‐Morales, A. SOCS2 deletion protects against hepatic steatosis but worsens insulin resistance in high‐fat‐diet‐fed mice. FASEB J. 26, 3282–3291 (2012). www.fasebj.org

1 January 2007 in Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
OVOscar Vidal
Oscar Vidal
RMRoxana Merino
Roxana Merino
ERElizabeth Rico-Bautista
Elizabeth Rico-Bautista
LFLeandro Fernandez-Perez
Leandro Fernandez-Perez
DCDennis J. Chia
Dennis J. Chia
AFAmilcar Flores-Morales
Amilcar Flores-Morales
The GH-activated signal transducer and activator of transcription 5b (STAT5b) is an essential regulator of somatic growth. The transcriptional response to STAT5b in liver is poorly understood. We have combined microarray-based expression profiling and phylogenetic analysis of gene regulatory regions to study the interplay between STAT5b and GH in the regulation of hepatic gene expression. The acute transcriptional response to GH in vivo after a single pulse of GH was studied in the liver of hypophysectomized rats in the presence of either constitutively active or a dominant-negative STAT5b delivered by adenoviral gene transfer. Genes showing differential expression in these two situations were analyzed for the presence of STAT5b binding sites in promoter and intronic regions that are phylogenetically conserved between rats and humans. Using this approach, we showed that most rapid transcriptional effects of GH in the liver are not results of direct actions of STAT5b. In addition, we identified novel STAT5b cis regulatory elements in genes such as Frizzled-4, epithelial membrane protein-1, and the suppressor of cytokine signaling 2 (SOCS2). Detailed analysis of SOCS2 promoter demonstrated its direct transcriptional regulation by STAT5b upon GH stimulation. A novel response element was identified within the first intron of the human SOCS2 gene composed of an E-box followed by tandem STAT5b binding sites, both of which are required for full GH responsiveness. In summary, we demonstrate the power of combining transcript profiling with phylogenetic sequence analysis to define novel regulatory paradigms.

14 December 2009 in Oncogene
Verified
Journal Article
Closed access
YCY-C Chuan
Y-C Chuan
DIDiego Iglesias-Gato
Diego Iglesias-Gato
LFLeandro Fernandez-Perez
Leandro Fernandez-Perez
ACA Cedazo-Minguez
A Cedazo-Minguez
SPS-T Pang
S-T Pang
AFA Flores-Morales
A Flores-Morales